Dare Bioscience Stock Performance
| DARE Stock | USD 1.70 0.02 1.16% |
The firm shows a Beta (market volatility) of 1.15, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Dare Bioscience will likely underperform. At this point, Dare Bioscience has a negative expected return of -0.0128%. Please make sure to confirm Dare Bioscience's kurtosis, and the relationship between the maximum drawdown and rate of daily change , to decide if Dare Bioscience performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Dare Bioscience has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Dare Bioscience is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Last Split Factor 1:12 | Dividend Date 2017-07-20 | Last Split Date 2024-07-01 |
1 | Acquisition by Steele Robin Joan of 45000 shares of Dare Bioscience at 1.35 subject to Rule 16b-3 | 11/18/2025 |
2 | Dar Bioscience Receives 3.6 Million in Additional Grant Funding | 11/24/2025 |
3 | Acquisition by Matz Gregory W of 45000 shares of Dare Bioscience at 1.03 subject to Rule 16b-3 | 11/28/2025 |
4 | DARE HC Wainwright Co. Reiterates Buy Rating with 12 Targe - GuruFocus | 12/02/2025 |
5 | Dar Bioscience Issues Updated Investor Corporate Presentation - TipRanks | 01/06/2026 |
6 | Acquisition by Haring-layton Mardee of 49000 shares of Dare Bioscience at 1.81 subject to Rule 16b-3 | 01/30/2026 |
7 | Telehealth Now Available for DARE to PLAY Sildenafil Cream First Evidence-Based Topical Arousal Cream for Women | 02/11/2026 |
| Begin Period Cash Flow | 10.8 M | |
| Total Cashflows From Investing Activities | -573 K |
Dare Bioscience Relative Risk vs. Return Landscape
If you would invest 181.00 in Dare Bioscience on November 15, 2025 and sell it today you would lose (10.50) from holding Dare Bioscience or give up 5.8% of portfolio value over 90 days. Dare Bioscience is currently does not generate positive expected returns and assumes 4.2089% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Dare, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Dare Bioscience Target Price Odds to finish over Current Price
The tendency of Dare Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.70 | 90 days | 1.70 | about 87.83 |
Based on a normal probability distribution, the odds of Dare Bioscience to move above the current price in 90 days from now is about 87.83 (This Dare Bioscience probability density function shows the probability of Dare Stock to fall within a particular range of prices over 90 days) .
Dare Bioscience Price Density |
| Price |
Predictive Modules for Dare Bioscience
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Dare Bioscience. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Dare Bioscience Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Dare Bioscience is not an exception. The market had few large corrections towards the Dare Bioscience's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Dare Bioscience, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Dare Bioscience within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.1 | |
β | Beta against Dow Jones | 1.15 | |
σ | Overall volatility | 0.18 | |
Ir | Information ratio | -0.02 |
Dare Bioscience Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Dare Bioscience for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Dare Bioscience can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Dare Bioscience generated a negative expected return over the last 90 days | |
| Dare Bioscience may become a speculative penny stock | |
| Dare Bioscience has high historical volatility and very poor performance | |
| Dare Bioscience has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 9.78 K. Net Loss for the year was (4.05 M) with loss before overhead, payroll, taxes, and interest of (14.35 M). | |
| Latest headline from globenewswire.com: Telehealth Now Available for DARE to PLAY Sildenafil Cream First Evidence-Based Topical Arousal Cream for Women |
Dare Bioscience Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Dare Stock often depends not only on the future outlook of the current and potential Dare Bioscience's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Dare Bioscience's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 8.5 M | |
| Cash And Short Term Investments | 15.7 M |
Dare Bioscience Fundamentals Growth
Dare Stock prices reflect investors' perceptions of the future prospects and financial health of Dare Bioscience, and Dare Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dare Stock performance.
| Return On Equity | -25.43 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 4.58 M | ||||
| Shares Outstanding | 13.48 M | ||||
| Price To Earning | (43.44) X | ||||
| Price To Book | 8.65 X | ||||
| Price To Sales | 751.51 X | ||||
| Revenue | 9.78 K | ||||
| Gross Profit | (14.35 M) | ||||
| EBITDA | (23.41 M) | ||||
| Net Income | (4.05 M) | ||||
| Cash And Equivalents | 40.39 M | ||||
| Cash Per Share | 0.48 X | ||||
| Total Debt | 1.3 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 2.17 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | 5.39 M | ||||
| Earnings Per Share | (1.83) X | ||||
| Market Capitalization | 22.92 M | ||||
| Total Asset | 22.1 M | ||||
| Retained Earnings | (175.29 M) | ||||
| Working Capital | (3.16 M) | ||||
| Current Asset | 7.58 M | ||||
| Current Liabilities | 17.82 M | ||||
About Dare Bioscience Performance
By analyzing Dare Bioscience's fundamental ratios, stakeholders can gain valuable insights into Dare Bioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Dare Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dare Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -270.4 K | -256.9 K | |
| Return On Tangible Assets | (0.18) | (0.17) | |
| Return On Capital Employed | (42.89) | (40.74) | |
| Return On Assets | (0.18) | (0.17) | |
| Return On Equity | 0.61 | 0.64 |
Things to note about Dare Bioscience performance evaluation
Checking the ongoing alerts about Dare Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dare Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dare Bioscience generated a negative expected return over the last 90 days | |
| Dare Bioscience may become a speculative penny stock | |
| Dare Bioscience has high historical volatility and very poor performance | |
| Dare Bioscience has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 9.78 K. Net Loss for the year was (4.05 M) with loss before overhead, payroll, taxes, and interest of (14.35 M). | |
| Latest headline from globenewswire.com: Telehealth Now Available for DARE to PLAY Sildenafil Cream First Evidence-Based Topical Arousal Cream for Women |
- Analyzing Dare Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dare Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Dare Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dare Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dare Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dare Bioscience's stock. These opinions can provide insight into Dare Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Dare Stock analysis
When running Dare Bioscience's price analysis, check to measure Dare Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dare Bioscience is operating at the current time. Most of Dare Bioscience's value examination focuses on studying past and present price action to predict the probability of Dare Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dare Bioscience's price. Additionally, you may evaluate how the addition of Dare Bioscience to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |